INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Alkermes plc - Ordinary Shares (ALKS)
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-irhome
Company Research
Source: Business Wire
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (“Alkermes” or “the Company”) (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The FDA issued a briefing document about Alkermes’ new drug application for ALKS 5461 on October 30, 2018, in advance of an FDA advisory committee meeting about the drug. According to the briefing document, Alkermes “used an abridged 6-item version of the MADRS-10 for the primary endpoint of one of the principal studies” instead of the “10-item diagnostic questionnaire (
Show less
Read more
Impact Snapshot
Event Time:
ALKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALKS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALKS alerts
High impacting Alkermes plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ALKS
News
- Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 [Yahoo! Finance]Yahoo! Finance
- Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1PR Newswire
- Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1PR Newswire
- Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition? [Yahoo! Finance]Yahoo! Finance
- Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
ALKS
Earnings
- 2/15/24 - Miss
ALKS
Sec Filings
- 4/15/24 - Form ARS
- 4/15/24 - Form DEFA14A
- 4/15/24 - Form DEF
- ALKS's page on the SEC website